

TG THERAPEUTICS INVESTOR & ANALYST FIRESIDE CHAT EVENT



ULTRA-V
— U2-V IN CLL —



UNITY CLL
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA UMBRALISIB (TGR-1202)
PHASE 3 TRIAL IN CLL



UNITY NHL
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA UMBRALISIB (TGR-1202)
PREVIOUSLY TREATED NHL PATIENTS

PARTICIPANTS

- *Paul Barr, MD, University of Rochester*
- *Javier Pinilla, MD, Moffitt Cancer Center*
- *Pier Luigi Zinzani, MD, University of Bologna*
- *Brian Koffman, MD, CLL Society*

Moderators

- *Alethia Young – Cantor Biotech Analyst*
- *Michael S. Weiss – TG CEO*



Indolent Lymphoma

Marginal Zone Lymphoma (MZL)

- *Current treatment paradigm*
- *Views on current therapies (Ibrutinib/R2...)*
- *Importance of tolerable agents*
- *Impressions on umbra MZL data and potential position in landscape*

 **ULTRA-V**
— U2-V IN CLL —**UNITY** **CLL**
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA UMBRALISIB (TGR-1202)
PHASE 3 TRIAL IN CLL**UNITY** **NHL**
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA UMBRALISIB (TGR-1202)
PREVIOUSLY TREATED NHL PATIENTS

Indolent Lymphoma

Follicular Lymphoma (FL)

- *Current treatment paradigm*
- *Views on the current therapies (Deltas/R2/Ibrutinib)*
- *Importance of tolerability*
- *The role of umbralisib in future treatment landscape*



ULTRA-V
U2-V IN CLL



UNITY^{CLL}
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA UMBRALISIB (TGR-1202)
PHASE 3 TRIAL IN CLL



UNITY^{NHL}
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA UMBRALISIB (TGR-1202)
PREVIOUSLY TREATED NHL PATIENTS

Chronic Lymphocytic Leukemia

- *Current treatment paradigm*
- *Academic v community setting*
- *Concerns with current treatment options*
- *Treatment choice & tolerability – important factors to think about*
- *Thoughts on position of U2 within treatment paradigm*



ULTRA-V
U2-V IN CLL



UNITY^{CLL}
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA UMBRALISIB (TGR-1202)
PHASE 3 TRIAL IN CLL



UNITY^{NHL}
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA UMBRALISIB (TGR-1202)
PREVIOUSLY TREATED NHL PATIENTS

Future of CLL: Combinations & Time Limited Therapy

- *Goal of combination v time limited therapy*
- *Current hot combinations*
- *Thoughts on combining BTK + Ven*
- *Impressions of U2 + Ven data*
- *Thoughts on TG pipeline - U2 plus _____*



ULTRA-V
U2-V IN CLL



UNITY CLL
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA UMBRALISIB (TGR-1202)
PHASE 3 TRIAL IN CLL



UNITY NHL
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA UMBRALISIB (TGR-1202)
PREVIOUSLY TREATED NHL PATIENTS

Thank you!



ULTRA-V
— U2-V IN CLL —



UNITY **CLL**
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA UMBRALISIB (TGR-1202)
PHASE 3 TRIAL IN CLL



UNITY **NHL**
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA UMBRALISIB (TGR-1202)
PREVIOUSLY TREATED NHL PATIENTS